Vestmark Advisory Solutions Inc. Purchases 24,262 Shares of Illumina, Inc. $ILMN

Vestmark Advisory Solutions Inc. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 101.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,092 shares of the life sciences company’s stock after purchasing an additional 24,262 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Illumina were worth $4,588,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Rise Advisors LLC increased its stake in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after buying an additional 224 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new position in shares of Illumina during the 2nd quarter worth approximately $41,000. NewSquare Capital LLC raised its stake in Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after acquiring an additional 369 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after acquiring an additional 558 shares during the period. Finally, Center for Financial Planning Inc. lifted its holdings in Illumina by 42.4% during the 2nd quarter. Center for Financial Planning Inc. now owns 588 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 175 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $121.90 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $154.43. The stock has a market capitalization of $18.63 billion, a P/E ratio of 15.43, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The stock has a fifty day moving average of $100.51 and a 200-day moving average of $94.30.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period last year, the company earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on ILMN. Morgan Stanley raised their price objective on shares of Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. UBS Group upped their price objective on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Stephens set a $110.00 target price on Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a research report on Wednesday, October 8th. Finally, Scotiabank lowered shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target on the stock. in a research report on Friday, July 11th. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $115.00.

Insider Activity

In other Illumina news, Director Scott Gottlieb bought 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.